Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Correction of Interim Report January – March 2018

Error in Camanio Care AB (publ) interim report January - March 2018 and in the press release 2018-05-15 regarding presentation of the report.When presenting the Group's revenues and expenses, Group internal items of SEK 530,000 are included. This means that the Group's revenues and expenses have been accounted for too high with the corresponding amount. The Group's earnings are not affected by this adjustment. The corrected interim report is available as a pdf-file on our website www.camanio.comand it is also attached to this press message. For further information, please contact:

NOTICE OF THE ANNUAL GENERAL MEETING FOR REALFICTION HOLDING AB (publ) AND PUBLICATION OF ANNUAL REPORT FOR 2017

The shareholders of Realfiction Holding AB (publ) (”the Company”) are hereby invited to attend the Annual General Meeting on Monday, June 18, 2018 at 14:00 CET at the Company’s premises with the address Terminalgatan 1, C/O Mazars SET Revisionsbyrå AB in Helsingborg. Registration will begin at 13.30 CET. The company also announces that the annual report for 2017 is now available on the company’s website, www realfiction.com . A printed copy can be ordered via investor@realfiction.com.RIGHT TO PARTICIPATE Those wishing to attend the General Meeting must - be

KALLELSE TILL ÅRSSTÄMMA I REALFICTION HOLDING AB (publ)

Aktieägarna i Realfiction Holding AB (publ) ("Bolaget") kallas härmed till årsstämma måndagen den 18 juni 2018 kl. 14.00 i Bolagets lokaler med adressen Terminalgatan 1, C/O Mazars SET Revisionsbyrå AB i Helsingborg. Registrering kan ske från kl. 13.30. Bolaget meddelar samtidigt att årsredovisningen för 2017 nu finns tillgänglig på bolagets hemsida, www.realfiction.com. Tryckt exemplar kan beställas via investor@realfiction.com.RÄTT TILL DELTAGANDE Rätt att delta på bolagsstämman har aktieägare som - dels är införd i eget namn i den av Euroclear förda aktieboken tisdagen den 12 juni

Net Gaming completes acquisition of assets in the DACH region

Net Gaming Europe AB, a leading global player of comparison websites within iGaming, completes the strategic acquisition of affiliate assets, primarily in the DACH region (Germany, Austria and Switzerland) from Webwiser Gmbh.On April 19, 2018, Net Gaming announced the signing of a Letter of Intent to this effect. Net Gaming has now signed an agreement to acquire these affiliate assets.The operations show strong growth and are currently generating quarterly sales of approximately EUR 200,000, with an operating margin of approximately 75%. About 75% of the revenues are generated via revenue

Neste renews its high-quality Futura gasolines – lower consumption, cleaner emissions

Neste Corporation Press Release 21 May 2018 9.30 a.m. (EET) Neste renews its high-quality Futura gasolines in Finland, all the Baltic countries as well as in Russia in the St Petersburg area. Neste’s Futura gasolines meet motorists’ growing expectations as well as offer lower fuel consumption and cleaner emissions. “Engine technology is developing rapidly, and this requires continuous fuel development as well. Our own research center in Porvoo is responsible for ensuring that we can offer our customers cleaner and lower-emission products that are especially developed for

Cantargia receives Notice of Allowance from USPTO for the antibody CAN03

Cantargia AB today announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company’s patent application 15/501,710 directed to the antibody CAN03, which is of relevance for Cantargia’s CANxx project.Cantargia develops antibody based pharmaceuticals against the interleukin 1 receptor accessory protein (IL1RAP). The lead project CAN04 is currently in clinical development for treatment of non-small cell lung cancer and pancreatic cancer. A second project, CANxx, is in preclinical phase with the aim to develop an antibody against IL1RAP for

INVISIO launches new versatile V10 control unit for the Special Forces community

Stockholm, May 21, 2017 INVISIO expands its product range by adding a new control unit for tactical communication and hearing protection. The new INVISIO V10 control unit is designed to meet Special Forces needs for a rugged, easy to use single-com system. The product will be presented at the Special Operations Forces Industry Conference, SOFIC, taking place in Tampa, Florida on May 21-24, 2018. Special Forces are trained for specific purposes and often require special skills and/or equipment. The INVISIO V10 is a rugged, light weight single-com PTT designed for soldiers with one

Terveystalo Plc: Disclosure under Chapter 9, Section 5 of the Securities Markets Act (Rettig)

TERVEYSTALO PLC       STOCK EXCHANGE RELEASE    21 May 2018 at 9.20 a.m. EEST Terveystalo Plc ("Terveystalo" or the "Company") has received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act (as amended, the "SMA") from Rettig Capital Oy Ab. According to the notification, the total holdings in Terveystalo shares and votes indirectly held by Rettig Capital Oy Ab (directly held by Rettig Group AB ("Rettig Group")) has increased to 16.52 percent (21,153,191 shares) of all of the outstanding shares in Terveystalo on 21 May 2018 as a result of a

Obducat receives order from customer in Germany

OBDUCAT AB (publ) subsidiary Obducat Europe GmbH, a leading supplier of system solutions for lithography processing, has received an order from an existing customer in Germany, for the supply of a QS W 775 Developer System. The order value amounts to 475.000 EUR.The QS W 775 Developer System, to be used for resist development and stripping, will be installed in the cleanroom facilities in customers’ manufacturing department. The customer already has several lithography processing systems from Obducat Europe GmbH. No further information can be disclosed at this time. Delivery of the QS W

Terveystalo Plc: Disclosure under Chapter 9, Section 5 of the Securities Markets Act (EQT)

TERVEYSTALO PLC       STOCK EXCHANGE RELEASE    21 May 2018 at 9.10 a.m. EEST Terveystalo Plc ("Terveystalo" or the "Company") has received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act (as amended, the "SMA") from EQT VI Limited. According to the notification, the total holdings in Terveystalo shares and votes indirectly held by EQT VI Limited (directly held by Lotta Holding I S.à r.l. ("Lotta Holding")) has decreased to zero on 21 May 2018 as a result of a transaction whereby Lotta Holding has sold its entire holding of 14,510,320 shares

Nordic Capital Fund IX to close at EUR 4.3 bn following strong demand

· Ninth fund expands its well established investor base, attracting highre-up rate and LP commitments from new geographies   · Demand reinforces Nordic Capital’s leading position in the Nordic region, global healthcare market and selected European sectorsNordic Capital today announced the successful final close of Nordic Capital Fund IX (“Fund IX”), at just over EUR 4.3 bn. The oversubscribed Fund exceeded its EUR 3.5 bn target in 7 months, and due to strong demand closing 23% above target. The new Fund enjoyed a re-up rate of over 70% from investors in predecessor funds, while

AstraZeneca PLC Announces Lokelma approved in the US for the treatment of adults with hyperkalaemia

Lokelma provides rapid and sustained potassium control for patients in a condition with high unmet need21 May 2018 07:00 BST The US Food and Drug Administration (FDA) has approved Lokelma (sodium zirconium cyclosilicate), formerly ZS-9, for the treatment of adults with hyperkalaemia,1 a serious condition characterised by elevated potassium levels in the blood associated with cardiovascular, renal and metabolic diseases.2 The risk of hyperkalaemia increases significantly for patients with chronic kidney disease (CKD) and for those who take common medications for heart failure (HF),

Happy Beans tell a story of the journey of coffee beans from the plant to the cup

Paulig continues the discussion of the bright future of coffee and introduces different phases of coffee production with the journey of Happy Beans from plant to cup. Paulig aims at making the world’s best coffee and believes that it is possible only with high-quality, tasty beans that have gone through a happy value chain. Paulig introduced at the beginning of 2018 a horror scenario to friends of coffee: Blend 2080, a coffee without coffee. Paulig wants to offer enjoyable coffee experiences also in the future and the future joys of coffee will be ensured only through responsible

SaltX receives SunCool breakthrough order

– To deliver 8,000 collectors to Ghana over three years, order value of 55 MSEK  Energy storage technology company SaltX Technology – listed on NASDAQ First North Premier – has received a breakthrough order of 8,000 SunCool-collectors from the solar energy provider SunAct in Ghana. The collectors are to be installed at thousands of sanitary stations throughout rural Ghana, most of which are off-grid. SunAct will be the provider of all energy including power, domestic hot water and cooling, and subcontracted to Thermodul Systems, which is under contract to build the stations for people in

Regulatory submission in Japan for Forxiga in type-1 diabetes

Regulatory submission in Japan for Forxiga in type-1 diabetes Japan submission follows European regulatory submission acceptance in March 2018 AstraZeneca has submitted a supplemental new drug application (sNDA) to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for the use of Forxiga (dapagliflozin), a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, as an oral adjunct treatment to insulin in adults with type-1 diabetes (T1D). The Japan sNDA is based on Phase III data from the DEPICT (Dapagliflozin Evaluation in Patients with Inadequately Controlled Type 1

KARO PHARMA RECEIVES MILESTONE PAYMENT FOR RORGAMMA PROJECT FROM PFIZER

Pfizer has informed Karo Pharma that a new milestone has been achieved. This means that Karo Pharma receives a payment of 6 MUSD. In December 2011, Karo Pharma entered a research collaboration and licensing agreement with the American company Pfizer. The aim of this agreement is to discover and develop compounds that inhibit the activity of the nuclear hormone receptor RORgamma, for treatment of autoimmune diseases. The development is lead by Pfizer according to the terms of the agreement. Pfizer has global exclusive rights to use, develop, manufacture and commercialize the compounds and

Release of the game Asylamba: Influence May 23, 2018 on Steam !

The Swiss studio RTFM Corp. is proud to present its new game Asylamba: Influence! This new title, a game combining strategy and puzzle-game in a futuristic and refined universe, will be available from May 23, 2018 at 7pm CEST (10am PDT) on the Steam video game platform, the largest video game distribution platform in the world.The new game Asylamba: Influence is a strategy game based on the world of Asylamba (see first game). This time it is a single-player game available on PC, Mac and Linux. Although the game is based on the same universe, the game is totally different and reinvented.

Share buy-backs in Telia Company during week 20 2018

During the period 14 May, 2018 – 18 May, 2018, Telia Company AB (publ) (LEI code 213800FSR9RNDUOTXO25) has repurchased in total 2 520 000 own shares (ISIN: SE0000667925). The share buy-backs form part of the SEK 5 billion share buy-back programme that Telia Company announced on 20 April, 2018. The share buy-back programme, which runs between 23 April, 2018 and 22 March, 2019, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 (”MAR”) and the Commission Delegated Regulation (EU) No 2016/1052 (the “Safe Harbour Regulation”).During the period 14 May, 2018 – 18

Finnair CEO Pekka Vauramo leaves the company to join Metso Corporation

Finnair Plc         Stock Exchange Release        21 May 2018        at 8.30 a.m. EET Finnair’s CEO, Pekka Vauramo, has given notice of his resignation from the company to join Metso Corporation as their new CEO. He will leave Finnair at the latest in November 2018. The search for Vauramo’s successor starts today. “The Board of Finnair is naturally sad to see Pekka Vauramo leave the company, but we also respect his personal decision to take on another challenge. We thank Pekka for his leadership in the past five years and wish him lots of success in his future role,” says Jouko

Sobi emphasises commitment to haemophilia community at WFH 2018 World Congress

Recent data show quality-of-life improvements for patients treated prophylactically with Elocta® and Alprolix®, extended half-life haemophilia therapies. Swedish Orphan Biovitrum AB (publ)  (Sobi™)(STO:SOBI) will present data at the World Federation of Hemophilia (WFH) 2018 World Congress, in Glasgow, Scotland, 20-24 May, demonstrating the company’s ongoing commitment to transforming the standard of care for people with haemophilia. Sobi will present real-world data demonstrating improvements in quality-of-life measures, including physical activity and joint pain,

Kojamo plc: Kojamo is planning an initial public offering and listing on the official list of Nasdaq Helsinki

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, JAPAN, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Kojamo is planning an initial public offering and listing on the official list of Nasdaq Helsinki Stock exchange release May 21, 2018 at 8:00 a.m. EET Kojamo plc ("Kojamo" or the "Company," and together with its subsidiaries, the "Group" or "Kojamo Group") is

Advanced biofuels can be produced extremely efficiently, confirms industrial demonstration

A chance to switch to renewable sources for heating, electricity and fuel, while also providing new opportunities for several industries to produce large numbers of renewable products. This is the verdict of researchers from Chalmers University of Technology, Sweden, who now, after ten years of energy research into gasification of biomass , see an array of new technological achievements. "The potential is huge! Using only the already existing Swedish energy plants, we could produce renewable fuels equivalent to 10 percent of the

Lehto and Avara sign framework agreement formajor housing portfolio

Lehto Group PlcStock exchange release21 May 2018 at 07.00 EEST Lehto Asunnot Oy (a subsidiary of Lehto Group plc) and Avara have signed a framework agreement concerning a housing portfolio which includes construction of 340 apartments in five cities around Finland. Avara acquires portfolio for Avara Asuinkiinteistörahasto I Ky -PE fund.The units are located at Kalasatama in Helsinki and in Kirkkonummi, Hämeenlinna, Kuopio and Oulu. The transaction price is more than EUR 53 million. Some of the units are already under construction and most of the units will be completed during 2019

TC TECH makes equity issue worth SEK 14 million

TC TECH’s Board of Directors has decided to make a directed equity issue of 1,217,800 shares, based on the authorization granted by the AGM held on 16 May 2018. As a result of this resolution, the company’s share capital will increase by SEK 97.4 thousand and liquid funds by around SEK 14 million.The subscribers in the share issue are institutional and private investors, who is characterized by a strong focus on commitment and perseverance. The subscription price will be SEK 11,50 per share, based on the VWAP in the ten-day period preceding the decision by the Board (SEK 12:66) reduced

There are no items matching the current filter
There are no more items matching the current filter
Back to top